Article | July 17, 2026

Model eCTD 4.0 readiness with digital twins   

Imagine you're the CIO of a mid-size pharmaceutical company. You know eCTD 4.0 is coming. You also know your enterprise resource planning (ERP) system needs modernizing, your Identification of Medicinal Products (IDMP) compliance program is running in parallel, and your regulatory operations team is already stretched thin managing submissions in the current format.

Now imagine trying to juggle all these efforts at once — without a clear view of how they interact.

That's the reality for most life sciences companies right now. Each initiative has its own timeline, its own team and its own validation requirements. Planned separately, they risk breaking each other. One wrong dependency could delay a filing, trigger revalidation or create audit exposure.

What if you could test the consequences before you committed?

Digital twins can help

Most people associate digital twins with manufacturing floors or supply chains. But in life sciences, an enterprise digital twin does something more fundamental: it models how data, processes and people interact across validated systems — giving leaders a way to see what a rule change, a workflow redesign or a platform upgrade will actually do before it hits production.

For eCTD 4.0 readiness, that means you could model the intersection of new submission metadata structures, structured product data, and your planned platform changes — and see where the risk concentrates before budgets and validation plans are locked in.

eCTD and beyond

Hybrid environments where companies run eCTD 3.x and 4.0 submissions in parallel during the transition is complex enough on its own.  But things can get even more difficult. 

For example, IDMP creates a new data layer underneath everything. The European Medicines Agency (EMA) is moving toward a unified digital model of medicinal portfolios — replacing static Article 57 records with high-fidelity, ISO IDMP-compliant data objects. By the end of 2026, every authorized medicine in the EU must make this transition. That means your product master data — substance, organization, referential and product information — needs to be structured, harmonized, and machine-readable. If your current systems hold that data in PDFs, spreadsheets or siloed databases, you have a data transformation problem running in parallel with your submission format change. 

ERP modernization touches the same data. Many pharma companies still operate on legacy ERP platforms built a decade or more ago — before IDMP, before eCTD 4.0, before current compliance demands. Leading firms are migrating to SAP S/4HANA or equivalent platforms for real-time integration and compliance automation. But pharma ERP implementation carries uniquely high stakes: an error in a batch record or quality process can directly impact patient safety. These migrations require formal validation, and they touch the same master data that IDMP needs structured and that eCTD 4.0 submissions reference. 

Here's where it gets dangerous. These three programs are typically run in separate lanes: 

• Regulatory teams tackle eCTD or IDMP readiness 
• IT modernizes applications and ERP 
• Operations pushes automation 
• Finance sponsors the ERP renewal 

But the business experiences the result as one connected system. When a new ERP instance changes how product data is stored, it can break the feed into your regulatory information management system. When IDMP requires restructured substance and product data, it can conflict with how your submission system references that same data for eCTD 4.0 lifecycle management. When all three change simultaneously without shared visibility, companies pay twice: once in project costs and again in rework, retesting and slower decision-making. 

The costliest failures in a regulated enterprise are rarely machine failures. They are handoff failures, metadata errors, duplicate validation work and late discovery that one system change has disrupted a downstream process. 

eCTD 4.0 introduces new complexity: new metadata structures, new lifecycle management requirements, new validation demands. And most companies will need to run 3.x and 4.0 submissions in parallel during the transition period. That hybrid environment is exactly where blind spots create risk.

Without  the right expertise, companies may face submission delays, validation failures, inconsistent metadata, increased rework, and additional pressure on already stretched regulatory teams. Organizations that begin preparing early can reduce implementation risk, streamline the transition, and position themselves to take advantage of the efficiencies and interoperability that eCTD 4.0 is designed to deliver.

A digital twin gives you visibility into that hybrid state. Combined with deep regulatory operations expertise — DXC built one of the first eCTD submission tools on the market and has delivered 76,000+ submissions with zero Refusals to File — it becomes a practical tool for:

• Managing hybrid environments safely — running 3.x and 4.0 in parallel without surprises
• Sequencing modernization intelligently — knowing which changes affect which downstream processes
• Turning compliance into a continuous discipline — not a final checkpoint that slows everything down

The hardest part of modernization in life sciences isn't choosing the next platform. It's understanding what that change will break somewhere else.

If you're facing eCTD 4.0, IDMP and enterprise renewal at the same time — and most companies are — the question isn't whether you can afford to model the risk first. It's whether you can afford not to.